Quantum BioPharma, a biopharmaceutical company listed on NASDAQ (QNTM), is committed to developing innovative solutions for neurodegenerative and metabolic disorders, including alcohol misuse disorders. Their subsidiary, Lucid Psycheceuticals Inc., focuses on advancing Lucid-MS, a novel compound that has demonstrated efficacy in preventing and reversing myelin degradation, a key factor in multiple sclerosis. Additionally, Quantum BioPharma […]